JPRN-jRCT2080221432未知3 期
A 24-week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Provision of informed consent prior to any study specific procedures
- •- Men or women age 20 years old or more (Either gender needs to be 40% or higher of total number of treated subjects)
- •- Diagnosed with type2 DM
排除标准
- •- Type 1 diabetes mellitus
- •- FPG more than 240 mg/dL before randomization
- •- Subjects who have history of unstable or rapidly progressing renal disease
- •- Subjects who have severe hepatic insufficiency and/or significant abnormal liver function
- •- Significant cardiovascular history
研究者
相似试验
进行中（未招募）
不适用
A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylurea) in Subjects with Type 2 Diabetes who Have Inadequate Glycaemic Control on Glimepiride Therapy AloneType 2 Diabetes MellitusEUCTR2007-005931-27-HUAstraZeneca AB545
进行中（未招募）
不适用
A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylurea) in Subjects with Type 2 Diabetes who Have Inadequate Glycaemic Control on Glimepiride Therapy AloneMedDRA version: 9.1Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitusType 2 Diabetes MellitusEUCTR2007-005931-27-CZAstraZeneca AB545
进行中（未招募）
不适用
A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylurea) in Subjects with Type 2 Diabetes who Have Inadequate Glycaemic Control on Glimepiride Therapy AloneType 2 Diabetes MellitusEUCTR2007-005931-27-PLAstraZeneca AB545
进行中（未招募）
不适用
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin. - GALLANT 14Men or women diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents, and with diabetic dyslipidaemiaie low HDL-C.MedDRA version: 7Level: LLTClassification code 10045242EUCTR2004-002550-56-DEAstraZeneca AB1,000
进行中（未招募）
1 期
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin. - GALLANT 14Men or women diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents, and with diabetic dyslipidaemiaie low HDL-C.MedDRA version: 7Level: LLTClassification code 10045242EUCTR2004-002550-56-CZAstraZeneca AB1,000